Equity Profile

SRPT

Sarepta Therapeutics, Inc.

Health CareBiotechnology$1.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical indicator of the company's profitability and financial health, which investors closely monitor.

Not available

Revenue Growth

Revenue growth is essential for understanding the company's market performance and acceptance of its products.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD). As part of the healthcare sector, its advancements could significantly impact patient lives and the broader biotech landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

In Q1-2026, Sarepta reported an EPS of $3.16, significantly surpassing expectations by over 700%. This positive surprise led to a stock increase of 5.69% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Sarepta's earnings report, especially after the strong performance last quarter. However, the lack of guidance adds uncertainty to expectations.

Bull Case

If Sarepta continues to demonstrate strong earnings and positive developments in its pipeline, it could see significant stock appreciation.

Bear Case

On the other hand, if the company fails to meet expectations or provides no clear guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated status of Sarepta's drug pipeline, particularly for DMD treatments?

The market will closely watch for any advancements or setbacks in the pipeline, as these could significantly influence future revenue and investor confidence.

Will the company provide any guidance for the upcoming quarters?

Management guidance is crucial for setting investor expectations and assessing the company's outlook, especially after a strong previous quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Sarepta's recent advancements in its drug pipeline, particularly for DMD treatments, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Sarepta's last quarter showed a remarkable EPS surprise, indicating strong operational performance.

The options market is pricing in a modest move, suggesting that investors may not fully appreciate the potential upside.

The company's historical performance shows a tendency to exceed expectations, which could be overlooked.

Key Risk

If the company provides strong updates on its pipeline, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued strong performance against the risks of unmet expectations and pipeline challenges.

Bull Confirmed If

A positive update on the drug pipeline, particularly with new data supporting DMD treatments, could confirm the bull case.

Bear Confirmed If

Conversely, any negative news regarding pipeline developments or a lack of guidance could validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a potential move of about 4.61%, indicating some uncertainty but not extreme volatility.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations and raises guidance, history suggests a potential stock increase of around 0.82%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history indicates a potential decline of about 12.94%, reflecting bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of DMD therapies in the pipeline.
2Any commentary on potential partnerships or collaborations.
3Insights into the company's revenue projections for the next quarters.
4Management's view on market competition and positioning.
5Details on upcoming clinical trials and their expected timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical indicator of the company's profitability and financial health, which investors closely monitor.

Not available

Revenue Growth

Revenue growth is essential for understanding the company's market performance and acceptance of its products.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

In Q1-2026, Sarepta reported an EPS of $3.16, significantly surpassing expectations by over 700%. This positive surprise led to a stock increase of 5.69% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Sarepta's earnings report, especially after the strong performance last quarter. However, the lack of guidance adds uncertainty to expectations.

Bull Case

If Sarepta continues to demonstrate strong earnings and positive developments in its pipeline, it could see significant stock appreciation.

Bear Case

On the other hand, if the company fails to meet expectations or provides no clear guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated status of Sarepta's drug pipeline, particularly for DMD treatments?

The market will closely watch for any advancements or setbacks in the pipeline, as these could significantly influence future revenue and investor confidence.

Will the company provide any guidance for the upcoming quarters?

Management guidance is crucial for setting investor expectations and assessing the company's outlook, especially after a strong previous quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Sarepta's recent advancements in its drug pipeline, particularly for DMD treatments, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Sarepta's last quarter showed a remarkable EPS surprise, indicating strong operational performance.

The options market is pricing in a modest move, suggesting that investors may not fully appreciate the potential upside.

The company's historical performance shows a tendency to exceed expectations, which could be overlooked.

Key Risk

If the company provides strong updates on its pipeline, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued strong performance against the risks of unmet expectations and pipeline challenges.

Bull Confirmed If

A positive update on the drug pipeline, particularly with new data supporting DMD treatments, could confirm the bull case.

Bear Confirmed If

Conversely, any negative news regarding pipeline developments or a lack of guidance could validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a potential move of about 4.61%, indicating some uncertainty but not extreme volatility.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations and raises guidance, history suggests a potential stock increase of around 0.82%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history indicates a potential decline of about 12.94%, reflecting bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of DMD therapies in the pipeline.
2Any commentary on potential partnerships or collaborations.
3Insights into the company's revenue projections for the next quarters.
4Management's view on market competition and positioning.
5Details on upcoming clinical trials and their expected timelines.